







Kenneth Hoffman, MD, MPH SAMHSA Center for Substance Abuse Treatment Division of Pharmacologic Therapies

ONDCP Forum, July 28, 2006



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration www.samhsa.gov










- Sources and use
 - Legally produced pharmaceutical used safely under close medical supervision
 - Illegally produced clandestine labs used dangerously to give heroinlike effect
 - Can be weaponized for lethality and terrorism













- Schedule II pharmaceutical closely monitored
 - Has medical indications but high abuse potential
 - Perceived as 'safe' by general public
- Clandestine laboratory created substitute
 - Attempt heroin-like effect with very small dose
 - Benefit to distributor with high user overdose risk
- Users do not intend to overdose or die
 - Prevention and Treatment Programs work when implemented



- Current data based on unintended overdoses/deaths
- Understand different population groups
 - Casual users in groups non-conforming to 'healthy adult community norms'
 - Patients seeking additional pain relief or with impaired judgment/altered mental status
 - Addicts seeking euphoric effect no longer achieved by compulsive use of regular drug








Age in Years

National Survey on Drug Use and Health 2004








- Prevention Create & Maintain a Healthy Population
 - Decrease experimentation with harmful drugs
 - Decrease misuse of prescription drugs
 - Identify harmful drug use early and intervene
- Treatment Heal Patients with Specific Drug Use Disorders
 - Abuse or voluntary use despite adverse consequences
 - Dependence or compulsive uncontrolled use
 - Substance-related psychiatric or medical problems



- Community norms
 - School and Worksite expectations
 - Social network and peer support
 - Family values
 - Individual factors
- Communication between adults and children
 - Establishing trust and healthy relationships
 - Demonstrate caring, concern, fairness and competency









- Selected Programs
 - Strategic Prevention Framework State Incentive Grants
 - Drug-free Communities Support Program
 - Center for the Application of Prevention Technologies
 - Prevention Fellows
 - State Prevention Directors Leadership Academy
 - Drug-free Workplace and Drug-testing Program




- Screening and Brief Interventions in all healthcare settings
- Detoxification leading to Rehabilitation and Recovery
 - Levels of Care
 - Community Support Services
- Multi-dimensional Treatment and Recovery Services
 - Levels of Care
 - Interaction with Juvenile and Criminal Justice System
 - Interaction with Faith-based Organizations and Community



- American Society of Addiction Medicine, American Pain Society and American Academy of Pain Medicine (2001)
 - Addiction is a primary, chronic, neurobiologic disease with genetic, psychosocial and environmental factors influencing its development and manifestations. It is characterized by one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving.
- Diagnostic and Statistical Manual IV and International
 Classification of Diseases 10 = Substance Use Dependence

Number Receiving/Needing Treatment






National Survey on Drug Use and Health 2004




Feeling Need/Making Treatment Effort



21.1 Million Needing But Not Receiving Treatment for Illicit Drug or Alcohol Use





National Survey on Drug Use and Health 2003-2004



- Selected Programs
 - Opioid Treatment Program Accreditation and Certification
 - Buprenorphine Waiver Program
 - Co-occuring Center for Excellence
 - Targeted Capacity Expansion Grants
 - Screening, Brief Intervention, Referral and Treatment grants
 - Access to Recovery vouchers
 - Addiction Technology Transfer Centers
 - Treatment Leadership Institute
 - Family and Juvenile Drug Courts
 - Treatment Locators



- Substance Abuse Prevention and Treatment Block Grant: Cornerstone of Demand Reduction
- Sciences to Services: Evidence-based Practices
- National Clearinghouse for Alcohol and Drug Information: Disseminating Knowledge to the Public
- Partnering with the Criminal Justice Community
- Enhancing the Use of Data: demonstrated today as we address the fentanyl problem



- General website <u>www.samhsa.gov</u>
- Model Programs and National Registry of Evidencebased Programs www.modelprograms.samhsa.gov
- Treatment Locators http://dasis3.samhsa.gov/
- Toll-free Referral Helpline 1-800-662-4357 (HELP)
- Questions?
 - Kenneth Hoffman, MD, MPH
 kenneth.hoffman@samhsa.hhs.gov